




## Third Annual World TB Day Symposium: *"Showcasing Clinical and Epidemiologic Studies on TB at the UW"*

March 24, 2016

David Horne, MD, MPH Jessica Matthews, MPH Alexandra Molnar, MD Masa Narita, MD David Park, MD





### **TB Project ECHO®**

TB Project ECHO<sup>®</sup> (Extension for Community Healthcare Outcomes) is a collaborative model, between the Washington State Department of Health, UW Telemedicine, and Firland Northwest Tuberculosis Center.

Medical education and care management for clinicians:

Bi-monthly sessions
TB specialists as mentors
CME/CNE credits





## **TB Project ECHO®**







#### **Tribal TB Needs Assessment**

Collaboration between Northwest Center for Public Health Practice (NWCPHP), FNWTBC, and Northwest Portland Area Indian Health Board (NPAIHB)

#### Key findings:

Through the needs assessment we identified the following TB training preferences:

Top Training Needs	Key Factors in Selecting Trainings	Preferred Formats	Target Audiences
• Pediatric TB	Offered during work     hours	<ul> <li>Online module (self- paced learning)</li> </ul>	•Clinics (local & county)
•Legal issues related to TB	•Reputation of trainer	•Live webinar	•Public health nurses
•LTBI in other special populations	•Using a case or problem-based learning approach	•Pre-recorded webinar	•Tribal health departments or corporations









## Annual / Ongoing Activities

## Seattle TB Intensive with Curry International Tuberculosis Center and WA Dept of Health : June

World TB Day : March World TB Day Evening Event, 5:30-7:45 Seattle Public Library Downtown 1000 4th Ave Tonight!

**Publications :** 

- Journal of AIDS (1)
- American Journal of Respiratory and Critical Care Medicine (2)





#### Acknowledgments





HARBORVIEW MEDICAL CENTER



Division of Pulmonary & Critical Care Medicine University of Washington





### Symposium Agenda

3:30 – 3:35 : Firland Northwest Tuberculosis Center Introduction

**3:35 – 3:55 : Bijan Ghassemieh, MD : "Social Determinants of Health and TB"** 

**3:55 – 4:15 : Adelaide McClintock, MD : "Latent TB Infection and** *Treatment in Vulnerable Populations in Seattle"* 

4:15 – 4:30 : Final Q&A

4:30 – 5:00 : Refreshments in R&T Lobby









## **Social Determinants of Health and TB**

March 24, 2016

#### **Third Annual World TB Day Symposium:**

"Showcasing Clinical and Epidemiologic Studies on TB at the UW"

Bijan Ghassemieh, MD

University of Washington Division of Pulmonary and Critical Care Medicine Senior Fellow

### SOCIAL DETERMINANTS OF HEALTH (SDH)

•<u>CDC</u>: "The complex, integrated, and overlapping social structures and economic systems that are responsible for most health inequities. These social structures and economic systems include the social environment, physical environment, health services, and structural and societal factors."



#### HINCHE, HAITI







#### HINCHE, HAITI







#### **WHO DOTS PROGRAM: 5 ELEMENTS**

1.) Political commitment with increased and sustained financing

2.) Case detection through quality assured bacteriology

3.) Standardized treatment, with supervision and patient support


4.) An effective drug supply and management system

5.) Monitoring and evaluation system






#### HINCHE, HAITI











#### **IDEAS ABOUT SDH AND TB ARE NOT NEW**


•Rudolph Virchow (1860): TB epidemics are related to "disturbances that exist in the development of our populations, disturbances which arise from political and social institutions, and are therefore preventable"

•Robert Koch (1905 Nobel prize speech): "One of the most powerful weapons, if not the most powerful, which we can bring into use against TB are social welfare centers"




#### **TB MORTALITY: ENGLAND AND WALES**

 $\bigcirc$ 





#### **TB IN THE US: 1987-1993**




FIRLAND NORTHWEST TUBERCULOSIS CENTER UNIVERSITY of WASHINGTON

Cantwell, AJRCCM 1998




#### **SELF REPORTED TB HISTORY IN INDIA 2006**





#### $\mathcal{O}$

## HOW DO SDH CAUSE TB?



FIRLAND NORTHWEST TUBERCULOSIS CENTER UNIVERSITY of WASHINGTON

Lonnroth, WHO SDH Document 2010



#### **CONTRIBUTION OF INTERMEDIATE RISK FACTORS**

Risk factor (reference for relative risk and prevalence estimates respectively)	Relative risk for active TB disease (range)ª	Weighted prevalence, total population, 22 high TB burden countries <sup>b</sup>	Population attributable fraction (range) <sup>c</sup>
HIV infection (76, 132) <sup>d</sup>	26.7 (20.4–34.9)	0.9%	17.6% (13.7–22.1)
Malnutrition (121, 133) <sup>e</sup>	4.0 (2.0–6.0)	17.2%	34.1% (14.7–46.3)
Diabetes (126, 134)	3.1 (2.3–4.3)	3.4%	6.6% (4.1–9.9)
Alcohol use > 40g/day (123)f	2.9 (1.9–4.6)	7.9%	13.1% (2.8–10.3)
Active smoking (124, 135)9	2.6 (1.6–4.3)	18.2%	22.7% (9.9–37.4)
Indoor pollution (117, 118) <sup>h</sup>	1.5 (1.2–3.2)	71.1%	26.2% (12.4–61.0)

FIRLAND NORTHWEST TUBERCULOSIS CENTER UNIVERSITY of WASHINGTON

Lonnroth, WHO SDH Document 2010



#### **END TB STRATEGY 2015**

#### **PILLARS AND COMPONENTS**

#### 1. INTEGRATED, PATIENT-CENTRED CARE AND PREVENTION


- A. Early diagnosis of tuberculosis including universal drug-susceptibility testing, and systematic screening of contacts and high-risk groups
- B. Treatment of all people with tuberculosis including drug-resistant tuberculosis, and patient support
- C. Collaborative tuberculosis/HIV activities, and management of comorbidities
- D. Preventive treatment of persons at high risk, and vaccination against tuberculosis

#### 2. BOLD POLICIES AND SUPPORTIVE SYSTEMS

- A. Political commitment with adequate resources for tuberculosis care and prevention
- B. Engagement of communities, civil society organizations, and public and private care providers
- C. Universal health coverage policy, and regulatory frameworks for case notification, vital registration, quality and rational use of medicines, and infection control
- D. Social protection, poverty alleviation and actions on other determinants of tuberculosis

#### 3. INTENSIFIED RESEARCH AND INNOVATION

- A. Discovery, development and rapid uptake of new tools, interventions and strategies
- B. Research to optimize implementation and impact, and promote innovations





#### SO WHAT CAN WE DO?

Politics and Advocacy:
"Health in all policies"
"Think Globally, Act Locally"
Example: Food Waste



#### How 'Ugly' Fruits and Vegetables Can Help Solve World Hunger

About a third of the planet's food goes to vaste, often because of its looks. That's enough to feed two billion people.



Every year some six billion sounds of U.S. huits and regetables go unharvested or unable, often for aesthetic reasons.





#### SO WHAT CAN WE DO?

#### •<u>Research</u>:

- •Identify which SDH are impacting TB incidence, where they are impacting TB incidence, and how they are impacting TB incidence
- Identify which intermediate risk factors are at play in different environments
- •Test interventions targeting SDH and intermediate risk factors
- •Evaluate cost-effectiveness of these interventions

•Essentially, provide data for policy makers to understand where resource allocation outside of the health sector is most likely to have an impact on TB incidence






## **SDH RESEARCH EXAMPLE: INDIA 2006**


Risk Factor	Univariate OR and 95% CI (DHS)	Multivariate Odds Ratio (aOR) and 95% CI (DHS)
Smoking Cigarettes	1.49 (1.16–1.90)	0.77 (0.56-1.06)
Chewing Tobacco	2.12 (1.66-2.72)	1.38 (1.03–1.86)
Indoor Air Pollution (IAP)	3.07 (2.36-4.01)	2.00 (1.35-2.98)
Low Body Mass Index (BMI)	2.90 (2.39-3.51)	3.71 (2.84-4.83)
Alcohol Use- Daily	1.98 (1.16-3.37)	1.36 (0.73–2.55)
HIV Sero-prevalence	5.75 (2.46-13.43)	4.72(2.0-11.20)
Diabetes Mellitus	2.77 (1.67-4.59)	4.89 (2.73-8.76)
Age (per year)	1.04 (1.03–1.05)	1.06 (1.04–1.07)
Male Gender	1.72 (1.43-2.05)	1.83 (1.37–2.4)
Household density (rooms for sleeping/ people sleeping)	1.11 (1.07–1.15)	1.08 (1.03–1.14)
Family member with health insurance	0.46 (0.27-0.77)	0.59 (0.29–1.23)
Rural dwelling	1.86 (1.50-2.30)	0.91 (0.68-1.21)

100 1 S. A. B. S. A. A Second States 



Oxlade, PLoS One 2012





FIRLAND NORTHWEST TUBERCULOSIS CENTER UNIVERSITY of WASHINGTON

Oxlade, PLoS One 2015



### SO WHAT CAN WE DO?

#### •Public Health:

•Encourage inclusion of SDH variables in TB monitoring/evaluation programs


•Encourage TB partnerships with other sectors (similar to partnerships for TB/HIV and TB/tobacco cessation partnerships)


•Develop novel methods to target interventions towards groups with certain SDH

•Seattle-King County TB Program example of spatial methods




#### KING COUNTY TB CASES OVER TIME








#### PERCENT FOREIGN BORN 2008-2012



Source: ACS Produced by: APDE




#### PERCENT IN POVERTY 2008-2012



Source: ACS Produced by: APDE



#### PERCENT DIABETIC 2009-2013



Source: BRFSS Produced by: APDE



#### **ELIMINATING TB WILL REQUIRE ADDRESSING SDH**

•The White Plague: Tuberculosis, Man, and Society (Renes Dubos 1952):

"TB is a social disease.....its understanding demands that the impact of social and economic factors on the individual be considered as much as the mechanisms by which the tubercle bacilli cause damage to the human body."







## Latent Tuberculosis Infection and Treatment in Vulnerable Populations in Seattle

Third Annual World TB Day Symposium: "Showcasing Clinical and Epidemiologic Studies on TB at the UW"

#### Adelaide McClintock, MD

on behalf of the LTBI Study Group University of Washington Acting Instructor, General Internal Medicine Nothing to Disclose



## **Treatment Choices**

# **Choices**


## INH x9 months

### Rifampin x 4 months

## Weekly INH+ Rifapentine



## **LTBI Adherence Study**



N= 393





# **Participating Clinics**

# Harborview

#### King County International TB medicine

Infectious Diseases Employee Health

Pioneer Square







# **Choices**


## INH x9 months

#### Rifampin x 4 months

### Weekly INH+ Rifapentine



### **Percent Completing Therapy**




FIRLAND NORTHWEST TUBERCULOSIS CENTER UNIVERSITY of WASHINGTON

 $\mathcal{O}$ 




## Percent completing therapy in each clinic

 $\bigcirc$ 



#### Adjusted for type of monitoring and type of treatment


### **Type of Monitoring**



FIRLAND NORTHWEST TUBERCULOSIS CENTER UNIVERSITY of WASHINGTON

 $\mathcal{O}$ 






N=132


INH+Rifapentine
Rifampin only
INH only




Participants who did not complete therapy













RCULOSIS






100.0	
90.0	
80.0	
70.0	
60.0	
50.0	
40.0	
30.0	
20.0	
10.0	
0.0	Nausea/Vomiting Abdominal pain
	Nausea, vonnting Abdominal pain
N=131	INH+ Rifapentine









100.0		
90.0		
80.0		
70.0		
60.0		
50.0		
40.0		
30.0		
20.0		_
10.0		_
0.0		Other
N=13	1 🗧 INH+ Rifapentine 📕 Rifampin only 💻 INH only	Other



### **Exciting Discoveries**

# Rifampin alone has as good of completion rates as INH+Rifapentine

#### \*\*MAJOR cost differences!\*\*



FIRLAND NORTHWEST TUBERCULOSIS CENTER UNIVERSITY of WASHINGTON



### **Exciting Discoveries**

# Type of treatment offered was a strong predictor of treatment completion

#### monitoring type was not







### **Exciting discoveries**

#### King County TB clinic does a great job of treating LTBI







### Strategies to improve compliance

- Shorter therapy courses
- "Creative" DOT
- Incentive programs (homeless incentives)







### **Strategies to Improve Compliance**

- Focused visits
- Engage your team (outreach, RNs)
- Monthly clinic visits when able







# **Choosing for your patient**

INH x 9 months

Rifampin x 4 months Weekly INH+Rifapentine x 3 mo



FIRLAND NORTHWEST TUBERCULOSIS CENTER UNIVERSITY of WASHINGTON

# **Choosing for your patient**

INH x 9 months

Rifampin x 4 months

Ś

Weekly INH+ Rifapentine x 3 mo









INH x 9 months

Rifampin x 4 months Weekly INH+ Rifapentine x 3 mo

SLOW

Medium

FAST



FIRLAND NORTHWEST TUBERCULOSIS CENTER UNIVERSITY of WASHINGTON

# **Choosing for your patient**

INH x 9 months Rifampin x 4 months Weekly INH+ Rifapentine x 3 mo

Few interactions

Multiple interactions

Multiple interactions

# **Choosing for your patient**

INH x 9 months

Rifampin x 4 months Weekly INH+ Rifapentine x 3 mo

UNIVERSITY of WASHINGTON

IRLAND NORTHWEST TUBERCULOSIS CENTER

2 pills

9 pills\*



### Thank you

- Patients
- Clinic Colleagues
- LTBI Study Group\*
- Dept of Public Health TB clinic staff
- Curry Center
- Questions: <u>amolnar@uw.edu</u> or <u>ahearst@uw.edu</u>
  - \* Alex Molnar, MD, McKenna Eastment, MD, Addie McClintock, MD, Christy McKinney, PhD, MPH, Masa Narita, MD, Shireesha Dhanireddy, MD, David Park, MD, John Lynch, MD, MPH, Caroline Pitney, PharmD





#### **Final Q&A**





